Only recently, Phase 2 clinical study revealed the antipsychotic action of an agonist of novel molecular target for the treatment of schizophrenia—trace amine-associated receptor 1 (TAAR1)—that has no direct antagonistic action on D2 dopamine receptors [4]. The gene discussed is TAAR1; the disease is schizophrenia.